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Abstract
Background: Objectives of this work are to (1) present an ontological framework for the TNM classification system,
(2) exemplify this framework by an ontology for colon and rectum tumours, and (3) evaluate this ontology by
assigning TNM classes to real world pathology data.
Methods: The TNM ontology uses the Foundational Model of Anatomy for anatomical entities and BioTopLite 2 as a
domain top-level ontology. General rules for the TNM classification system and the specific TNM classification for
colorectal tumours were axiomatised in description logic. Case-based information was collected from tumour
documentation practice in the Comprehensive Cancer Centre of a large university hospital. Based on the ontology, a
module was developed that classifies pathology data.
Results: TNM was represented as an information artefact, which consists of single representational units. Corresponding
to every representational unit, tumours and tumour aggregates were defined. Tumour aggregates consist of the
primary tumour and, if existing, of infiltrated regional lymph nodes and distant metastases. TNM codes depend on the
location and certain qualities of the primary tumour (T), the infiltrated regional lymph nodes (N) and the existence of
distant metastases (M). Tumour data from clinical and pathological documentation were successfully classified with
the ontology.
Conclusion: A first version of the TNM Ontology represents the TNM system for the description of the anatomical
extent of malignant tumours. The present work demonstrates its representational power and completeness as well as
its applicability for classification of instance data.
Keywords: TNM classification, Tumour classification, Tumour staging, Anatomical extent, TNM ontology,
Description logic
Background
Clinical and pathological staging of malignant tumours is
one of the most important procedures in the diagnosis
of cancer for prognosis assessment and treatment plan-
ning. The staging procedure compiles several clinical and
pathological parameters such as the location and the size
of the primary tumour, the location and the number of
the infiltrated regional lymph nodes, and the existence of
distant metastases.
A prerequisite for an evidence-based cancer treat-
ment is a correct and unambiguous cancer diagnosis.
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Interdisciplinary expert groups, e.g. from clinical
medicine, imaging, and pathology, have been working in
close cooperation to establish criteria for precise tumour
diagnoses [1]. One of the most challenging tasks in
clinical oncology is to correctly classify and code clinical
findings, using a multitude of available coding systems.
By far, the most important coding system for tumour
staging is the Tumour-Node-Metastasis (TNM) classifica-
tion [2] formalignant tumours, published by the Union for
International Cancer Control (UICC)1. Besides a growing
number of reliable biomarkers, TNM classification and
staging are the most important information for the ther-
apy planning for patients with colorectal cancer [3–5] and
other solid tumours (e.g. cancer of the head and neck
[6] or breast tumours [7]), except cancers of the central
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nervous system. In addition, the TNM classification
system is important in cancer research for a cor-
rect description and classification of the anatomical
extent of a given tumour. This is not only rele-
vant for cancer epidemiology but also in fundamen-
tal tumour research (e.g. the dataset descriptions for
researchers of the Surveillance, Epidemiology, and End
Results Program (SEER) of the National Cancer Insti-
tute2 and predefined results using TNM stratified
data3).
The TNM coding procedure requires advanced skills,
encompassing both experience in tumour documentation
and in-depth domain knowledge. The criteria for classifi-
cation of the different primary tumour locations differ to
the same extent as the underlying diseases. As a conse-
quence, even expert coders and physicians for one organ
systemmight encounter difficulties in the correct applica-
tion or interpretation of TNM in a different organ system.
Several combinations of tumour findings are difficult to
encode due to ambiguous or overlapping criteria (non-
disjoint definitions) or non-exhaustive definitions, which
often result in cases where no TNM code or more than
one TNM code is applicable to a given tumour state. A
variety of problems with TNM coding has been described
for different tumour locations. Main issues that arise in
the practice of TNM coding derive from overly com-
plex definitions of the underlying medical situation, which
then result in interpretation problems even for experts
[8–10]. The required in-depth knowledge of the domain,
together with specific competences needed for TNM cod-
ing, result in poor coding completeness and quality, espe-
cially with the clinical staging in outpatients [11, 12].
Given the importance of TNM staging for the individual
patient, deviation rates of about 20% for clinical coding
and 10% for pathological coding can be interpreted as
very high [13].
The complexity of TNM is mainly due to the develop-
ment of the TNM classification as an evolutionary pro-
cess [14], which has been constantly incorporating huge
amount of new scientific insights in tumour prognosis and
the dependency of therapeutic effects on tumour stage.
Controlled by medical experts, TNM’s underlying struc-
ture has become more and more complex over the years.
Experts in different fields of oncology have demanded a
change in TNM maintenance, to address the increasing
complexity, the detachment from clinical practice, and the
resources needed for documentation [15, 16]. Therefore,
standardisation of tumour classification and staging is an
urgent requirement for improvement of tumour docu-
mentation in primary documentation, clinical studies and
cancer registries [11, 17–20].
Despite its importance and formal precision, to the
knowledge of the authors, no formal representation
of the complete TNM is available so far. Formal,
i.e. computable representations would have several advan-
tages over TNM’s current publication as a textbook.
An initial attempt to represent staging of lung tumours
and glioma tumours was not continued [21, 22]. More
recently, a description logics based (DL) approach was
presented [23].
One of the major requirements a formal representa-
tion of TNM could satisfy is the automatic classifica-
tion of instance data obtained from clinical databases
or mined from textual reports [24–26]. Consecutively,
instance data classification could inform higher order pro-
cesses such as clinical documentation systems. Instance
data on pathological or clinical conditions are collected
during routine health care processes in pathology or other
clinical information systems. Users could be supported
by automatic encoding of instance data to TNM in real
time or in spatially and temporally disseminated settings
(e.g. in tumour documentation). For intelligent documen-
tation systems in clinical oncology and pathology, a TNM
ontology could be deployed as part of the knowledge
base supporting the coding of tumour-related findings
and the interpretation of TNM codes. In such systems a
TNM ontology could enable automated reasoning based
in description logics, which would timely detect logical
inconsistencies and complexity related coding problems
in databases and textual reports. In integrated clinical
decisions support systems (DSS) TNM could be deployed
to inform users about guideline-conformant treatment
[27]. A further advantage of a formal approach would be
the enhanced support for development and refinement of
TNM.With a taxonomic backbone and axiomatic descrip-
tions, the current complex natural language descriptions
could be converted into computable structures. This
would help decompose the descriptions into all their
defining criteria, which in turn could facilitate the detec-
tion of coding errors, inconsistencies, and ambiguities in
definitions [28, 29].
Description logics is the method of choice for a for-
malization of TNM [30]. Advanced retrieval and query-
ing tools would be additional benefits that come with
a logical representation following principles of Applied
Ontology [31]. For these use cases, a formalised TNM
version could constitute a unified source on which a vari-
ety of clinical documentation and analysis tools could
be based. In addition, such a resource could be mapped
to other DL-based clinical ontologies, especially to
SNOMED CT.
With this work, we propose to close the gap of a miss-
ing formal representation by outlining and prototyping
the TNM ontology (TNM-O). Following up on initial
attempts in the breast cancer domain [32], the objectives
of this work are (1) to present an ontological framework
for the TNM classification system, (2) to implement a
TNM ontology, describing colon and rectum tumours
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based on this framework, and (3) to evaluate this ontology
using a tool for classifying pathology data.
The TNM classification
The canonical description of the TNM classification
based on the anatomic extent of disease (EOD) is pub-
lished by the UICC and the AJCC [2, 33]. The UICC
published the first edition of the TNM coding system
in 1968. Since then, the system has undergone sev-
eral revisions, with the 7th edition published in 2009.
The AJCC has recently announced the release of the
8th edition of the TNM classification for the beginning
of 20174. The part of the new version for lung can-
cer is already in use with its important changes satis-
fying urgent medical requirements [34]. The objectives
of the TNM coding system are six-fold. It supports
treatment planning, prediction of outcomes (prognosis),
evaluation of treatment results, exchange of information
between different participants in health care processes,
continuing research in malignant diseases, and cancer
control [2, 14].
The core TNM classification uses three descriptors: T
(tumour), N (metastasis in regional lymph nodes), and M
(distant metastasis). The extent of the disease is indicated
by integer values resp. character modifiers: TX (Tumour
cannot be assessed), T0 (No evidence of primary tumour),
T1-4 (increasing size or local extent), Tis (Carcinoma in
situ); NX (Regional lymph nodes cannot be assessed), N0
(No regional lymph node metastasis), N1-3 (Increasing
involvement of regional lymph nodes); M0 (No distant
metastasis), M1 (Distant metastasis). For some entities
further subdivisions of the categories are possible indi-
cated by lower case characters (e.g. N2a and N2b).
The specific medical denotation for the different
descriptors is dependent on the localisation of the tumour,
designated by the ICD-O localisation code5. It is not
possible to list all single regions addressed by the TNM
classification here (for a current list see [2]). However, the
TNM classification is not available for all body regions
or systemic malignancies (e.g. C70-C72 Tumours of the
Central Nervous System, C33 Trachea, C42, and C77
Tumours of haematopoietic and lymphoid tissues). For
most of these malignancies the anatomical extent is either
not determinable (systemic malignancies e.g. leukaemia)
or the tumours have no metastasis (e.g. CNS tumours).
The World Health Organisation (WHO) has published
the 3rd edition of International Classification of Diseases
for Oncology (ICD-O) in 2003. As an extension of the
International Classification of Diseases (ICD-10) [35] for
tumour diseases, the ICD-O is a dual classification system
for the tumour morphology and the tumour localisation
[36]. ICD-O is widely used in clinical medicine, tumour
documentation, and research to encode tumour morphol-
ogy and tumour localisation.
With an additional modifier, the TNM classification
is divided into the pre-treatment clinical (indicated as
cTNM) and post-surgical pathological (pTNM) classifica-
tion. pTNM codes can only be assigned to the disease after
pathological assessment following surgery and is the most
important diagnostic item for following (adjuvant) radio-
or chemotherapy or their combination. The results from
the clinical assessment have to be accurately discerned
from the pathological assessment due to their different
meanings and evidence levels.
Besides the already complex semantics of the main
numeric TNM codes, a series of additional symbols exists,
which might have largely different meanings in the differ-
ent tumour locations. Prefixes, suffixes, and certainty fac-
tors increase the confusion, e.g. for carcinoma in situ the
suffix “is” has to be used (“Tis”). As TNMallows putting an
“X” wherever the information about the clinical or patho-
logical situation is incomplete or inaccurate, incomplete
code assignments become widespread (e.g. MX for “no
statement on metastases possible”). In this work only the
classes with the descriptors T, N, andMwith themodifiers
c and p are represented (for a full list see Table 1).
Table 1 TNM classification descriptors and additional modifiers
Descriptor Values Meaning
T 0-4, is, X Extent of the primary tumour
N 0-3, X Extent of metastasis in regional
lymph nodes
M 0-1 Existence of distant metastasis
Prefix to T, N, M p, c Clinical (pre-therapeutical) or
pathological (post-surgical
assessment)
Suffix to pNn (mi) Micrometastasis (< 0.2 cm)
Suffix to pNn (sn) Sentinel lymph node metastasis
Suffix to pN0 or pM0 (i+), (mol+) Isolated tumour cells, positive
findings
G X, 1-4 Histopathological grading
Suffix to T (m) Multiple primary tumours at a
single side
Prefix to c/ p y Assessment during multimodal
therapy
Prefix to c/ p r Recurrent tumour
Prefix to c/ p a Assessment during autopsy
L X, 0-1 Lymphatic invasion
V X, 0-2 Venous invasion
Pn X, 0-1 Perineural invasion
C 1-5 Validity of the assessment, can
follow each of T, N, M
R X, 0-2 Residual tumour
Depending on the organ of the primary tumour, T, N, and M values can be further
subdivided into levels a-c, e.g. N1a-c, N2a-c, and M1a-b in colorectal tumours
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pTNM codes are grouped into stages which are based
on the prognosis of the patients. Stages are designated by
the roman numerals I-IV and further subdivided into sub-
stages described by capital letters A-C. TNM staging has
been subject to frequent changes during the history of
the TNM classification, according to scientific and medi-
cal progress [34]. The mapping of the TNM classification
for colon and rectum tumours to stages for version 7 is
provided in [2, 4].
Methods
TNM-O, the TNM ontology presented here, uses the
Foundational Model of Anatomy [37] for anatomical enti-
ties, together with BioTopLite 2 (BTL2) as a domain
top-level ontology [38, 39]. Tailored for the biomedical
domain and based on description logics [30], BTL2 pro-
vides upper-level types both for general categories like
Material object, Process, Information object, Quality etc.,
as well as constraints on all of them, using a set of sixteen
canonical relations, partly derived from the OBO Rela-
tion Ontology (RO) [40]. They constrain each category by
means of a set of general class axioms. BTL2 also contains
other axioms such as relationship chains, existential and
value restrictions. Thus, the building of domain ontolo-
gies under BTL2 heavily constrains the freedom of the
ontology engineer, which is fully intended as it guaran-
tees a higher predictability of the outcomes of the domain
ontology production under BTL2.
The design of BTL2 is top-level agnostic and has been
influenced both by the Basic Formal Ontology (BFO
and BFO2) and the Descriptive Ontology for Linguis-
tic and Social Engineering (DOLCE) which is discussed
in more detail in [39]. BTL2 is especially appropriate
as domain top-level for TNM-O because it provides a
lean, yet exhaustive ontological framework for the repre-
sentation of clinical documentation artefacts. Moreover,
it is fully axiomatised using RO (see above) so that it
is interoperable with other ontologies in the biomedical
domain.
The development of TNM-O is an ongoing process.
For this study, colorectal cancer was chosen as use case
for several reasons. It is the third most common cancer
worldwide and accounts for 9% of all cancer incidence
[41, 42], affecting more than one million humans in 2002.
Treatment of cancer patients and research on causes of
cancer are main goals of worldwide cancer control pro-
grams6. In prior work, the TNM classification for breast
tumours (ICD-O C50) had been formally represented
[32]. The selection of breast and colorectal tumours was
motivated both by their paramount medical importance
and their complexity in TNM, where both follow non-
trivial medical classification principles, especially for the
cN and pN classifications. Demonstrating the appropri-
ateness and feasibility of TNM-O for these two tumour
locations provides a good support for the general applica-
bility of the approach.
The general rules of the TNM classification and the spe-
cific TNM classification for tumours of the colon and the
rectum (ICD-O topography chapters C18 – C21, for ICD-
O morphology codes see Table 2) were represented as
described [2, 43].
A classifying tool for individuals (instances) derived
from pathology reports was developed employing the
OWL API (version 4.0.1)7 and the HermIT DL reasoner
(version 1.3.8)8. It classifies breast tumour and colorectal
tumour data based on the corresponding TNM ontolo-
gies. It reads either tabular input data from files or
processes data from manual entry via a graphical user
interface.
The objective of TNM-O is not to re-design an exist-
ing tumour classification into a new system. At the cur-
rent level of development, TNM-O is the result of an
ontological analysis of what has been developed by the
medical community over a long period, followed by its
translation into a formal language, incorporating onto-
logical principles, in order to improve the development,
maintenance, and application of the TNM classification
system.
In the following two sections, we describe (1) the TNM
classification in detail as foundation of what has to be rep-
resented by TNM-O, (2) how the TNM classification arte-
facts are represented by information artefacts of TNM-O,
(3) how these information artefacts are related to the
actual tumour entities, and (4) how the patho-anatomical
reality of tumour disease is constructed in terms of what
is required for the TNM classification.
Design of the TNM-O
The relation between the artefacts of the TNM
classification and the actual tumour diseases is denota-
tional: the T code denotes the extent (size, infiltration)
of the primary tumour, the N code the extent of regional
Table 2 ICD-O 3 morphology codes for tumours of the colon
and the rectum
Type ICO-O 3 morphology
Adenocarcinoma 8140/3
Mucinous adenocarcinoma 8480/3
Signet-ring cell carcinoma 8490/3
Small cell carcinoma 8041/3
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lymph node metastases, and the M code the existence of
distant metastases. For TNM-O, we adopted an approach
which is compliant with the Information Artefact Ontol-
ogy from the OBO Foundry and recently published
work on the aboutness relation [44, 45]. In TNM-O,
coding artefacts of the TNM classification i.e. the
classes of the classification are represented by subclasses
of btl2:InformationObject as RepresentationalArtefact.
Information reported on individual patients, e.g. as TNM-
codes in patient records are thus individuals of these
classes. Individuals from subclasses of InformationObject
are related by btl2:represents to individuals of classes
about the current disease state (AnatomicalStructure).
The inverse relation is btl2:isRepresentedBy connects
material or processual entities with the respective
TNM-artefact.
As the TNM classification is compositional, the individ-
ual classes of the three descriptors can be independently
combined to a joint code. Classes are only dependent on
the location of the primary tumour and additional mod-
ifiers c or p: e.g. cN1 for colon cancer has a different
meaning than cN1 for breast cancer, and cT1 has a differ-
ent meaning than pT1 for all locations where these codes
are available). This characteristic is conserved in TNM-
O. The class RepresentationalUnit is a superclass of organ
specific classes separated in a clinical and a pathological
branch.
For representing anatomical structure, TNM-O uses
content from the Foundational Model of Anatomy,
restricted to cancer-related anatomy as referred to by
the TNM classification. All primary tumours individuals
and metastases are then related to individuals anatomi-
cal entities by the relation btl2:locatedIn, thus providing
them with an exact topography and extent. The extent of
primary tumours cannot only be described by their local-
isation (i.e. occupying space or infiltrating through layers
of an organ) but can be further characterised by qualities,
e.g. tumour size or infiltration patterns. These qualities
are dependent on the localisation of the primary tumour
and can substantially differ between them.
What makes a lymph node a regional lymph node
depends on its proximity to a primary organ. An axillary
lymph node is a regional lymph node of the breast gland
but not of the colon. For all relevant organs, these regional
lymph node groups are to be defined. Moreover, the for-
malisation of infiltrated regional lymph nodes depends on
the aggregate of a localised primary tumour together with
some metastasis in a regional lymph node of that organ in
which the primary tumour is located. Thus, an infiltrated
axillary lymph node is a regional lymph node metastasis
for a breast tumour, but certainly not for a colon cancer.
Distant metastases are, by definition, those located in a
tumour aggregate that is not a regional lymph node of the
primary tumour.
Classification of pathology data
We computationally classified data describing the extent
of 291 colorectal cancer specimens into TNM, docu-
mented at the Institute of Surgical Pathology, Medical
Center – University of Freiburg using a pathology infor-
mation system. This data were re-coded as RDF-OWL
instance data and classified into classes of TNM-O by
an application based on the OWL API using an OWL
classifier9. Automatic classification was solely based on
axioms defined in the colorectal TNM-O version 7 (TNM-
O_colon_7.owl). The complete set of criteria is shown in
Table 3.
For comparison of the ontology-based TNM classi-
fication with a manual expert TNM classification, the
data were manually classified by a pathologist into TNM
version 7.
Results
TNM-O is designed as a modular system of independent
ontologies under BTL2. For every organ or organ system
based module of the TNM classification system, TNM-O
Table 3 Criteria of TNM version 7 for colorectal cancers. All TNM codes can be inferred from this criteria. The exact wording of the
textual definitions of the TNM in version 7 is diverging. Exact count of infiltrated organs in distant metastasis is omitted
Criterion btl2 superclass Value
Primary tumour extension MaterialObject Epithelium, Submucosa, Lamina propria, Subserosa, Adventitia, VisceralPeritoneum
Primary tumour growth pattern Quality Infiltrative, Confined
Primary tumour epistemology Quality NoAssessment, NoEvidence
Regional LN number Quality Cardinality1, Cardinality2or3, Cardinality4to6, Cardinality7orMore
Regional LN epistemology Quality NoAssessment, NoEvidence
Distant Mx location MaterialObject Peritoneum
Distant Mx/no. of organs Quality Cardinality1, Cardinality2orMore
Distant Mx epistemology Quality NoEvidence
http://cancerstaging.blogspot.de/2005/02/colon-and-rectum.html
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provides a set of specific ontologies. The TNM connect-
ing ontology serves as a hub to import BTL2 as well as
the organ and organ system specific TNM ontologies (see
Table 4). With the modular architecture only those mod-
ules are included that are needed by a tumour-specific
application.
The hub TNM Ontology for all tumours can be
downloaded from http://purl.org/tnmo/TNM-O.owl. The
ontologies for breast tumours and colorectal tumours
are named according to Table 4 and can be downloaded
from the same site. They need to be loaded in the hub
ontology.
Without inclusion of BTL2, the TNM hub ontology
has the description logic expressivity of ALC (for a
short introduction to the DL nomenclature see [46]
section Description Logic Nomenclature). It consists of
79 axioms, 38 logical axioms, and 39 classes. It includes
35 subClassOf and one EquivalentTo axioms. Most of
the classes are proxy classes to BTL2. Inclusion of BTL2
changes the DL expressivity to SRI.
The TNM ontology for colorectal tumours has the
description logic expressivity of ALC. For TNM version
7.0 (version 6.0 in brackets), it consists of 366 (357)
axioms, 198 (199) logical axioms, and 161 (149) classes. It
includes 123 (160) subClassOf, 57 (18) EquivalentTo and
18 (18) DisjointClasses axioms.
Representational units in the TNM-Ontology
The representation of the TNM system is decomposed
into the representational units T, N, and M, together
with the location of the primary tumour. Thus, for every
existing code Tn, Nn, and Mn in combination with a spe-
cific organ there exists one TNM-O:RepresentationalUnit
which is an btl2:InformationObject. E.g. every TNM
code for colorectal cancer is represented by a separate
class. Axioms using the relation btl2:isRepresentedBy
introduce possible TNM values for subclasses of Primary-
Tumour or TumourAggregate. This is done by connecting
Table 4 Modular structure of TNM-O. Codes in clinical
documentation and cancer registries follow TNM versions,
because the meaning of codes and stages may change between
versions. The modular structure is designed to include versions
for every available TNM encoded entity (tumour location) so that
the intended meaning is preserved according to the version
used for coding
Name Description
BTL2 Upper domain level ontology
TNM-O TNM-O central connecting ontology
TNM-O_breast_7 TNM-O for breast cancer (TNM version 7) in: [32]
TNM-O_colorectal_6 TNM-O for colorectal cancer (TNM version 6)
TNM-O_colorectal_7 TNM-O for colorectal cancer (TNM version 7)
these values via the universal quantifier ONLY (role
restriction). In all of these cases, the clause “or (not Repre-
sentationalUnitInTNMClassification)” allows other values
that are not TNM representational units. In the remaining








Representation of the primary tumour
The primary tumour is represented as PrimaryTumour, a
subclass of MalignantAnatomicalStructure. The tumour char-
acteristics relevant for the representational unit T of the
TNM classification system are represented as location and
qualities of PrimaryTumour. For colorectal tumours, the
exact localization of the tumour in the gut wall, the qual-
ity of the tumour confinement with respect to neighbour-
ing organs (confined or invasive), the quality of the assess-




(btl2:isBearerOf some (Confinement and
(btl2:projectsOnto some Invasive))) and
(btl2:isIncludedIn some
SubmucosaOfLargeIntestine)
The specific tumour defined as subclass of PrimaryTumour
above is directly related to the corresponding representational










Representation of regional lymph nodes
The most complex part of the TNM classification of many pri-
mary tumour locations is the interpretation of the axisN, which
describes the extent of infiltration of regional lymph nodes by
the primary tumour. The anatomy of lymph nodes draining the
colon and rectum was modelled according to clinical anatom-
ical conventions. Metastatic regional lymph nodes can exactly











To define regional lymph node metastases of colorectal
cancers, the aggregate of primary tumour and infiltrated
lymph nodes around the colon and rectum (TumourAggre-
gate) has to be considered as one (composite) entity. The
representational unit N of the TNM classification of col-
orectal cancers depends on the count of metastatic regional
lymph nodes and the presence of subserosal tumour deposits
without regional lymph node metastases. The count of












Representation of distant metastases
For the representational unitM of the TNM classification sys-
tem the existence and number of distant metastases are eval-
uated. The definition of distant metastases excludes regional
















Classification of pathology data
All instance data of 291 samples of colorectal cancer
could be classified into classes of TNM-O on colorectal
cancer. A posteriori comparison of the automatic classifi-
cation results with a manual TNM coding based on the
same findings from the pathology database by an experi-
enced pathologist showed 100% agreement. Table 5 shows
15 exemplary tabular instance data rows and the cor-
responding manual and automatic classification results.
Figures 1 and 2 shows an example of an RDF-OWL
instance which corresponds with rows 6 and 8 of Table 5.
For clarity, the RDF example focuses on TNM N, other
details on tumour invasion and distant metastasis were
left out. All automatic classification results are based on
Table 5 TNM relevant tabular data, manual expert TNM classification (subscript P), and ontology-based automatic TNM classification
(subscript O)
Invasion of rLN tp rLN TD/ Sat. dMT ip dMT TP NP MP TO NO MO
Subserosa 31 0 no 0 no pT3 pN0 M0 pT3 pN0 M0
Muscular layer 13 0 no 0 no pT2 pN0 M0 pT2 pN0 M0
Subserosa 19 0 no 0 no pT3 pN0 M0 pT3 pN0 M0
Submucosa 18 0 no 0 no pT1 pN0 M0 pT1 pN0 M0
Muscular layer 11 0 no 0 no pT2 pN0 M0 pT2 pN0 M0
Visc. peritoneum 19 2 no 0 no pT4a pN1b M0 pT4a pN1b M0
Subserosa 20 0 yes 0 no pT3 pN1c M0 pT3 pN1c M0
Subserosa 14 2 no 0 no pT3 pN1b M0 pT3 pN1b M0
Muscular layer 14 0 no 0 no pT2 pN0 M0 pT2 pN0 M0
Subserosa 24 4 no 0 no pT3 pN2a M0 pT3 pN2a M0
Other 16 6 no 0 no pT4b pN2a M0 pT4b pN2a M0
Subserosa 17 0 no 0 no pT3 pN0 M0 pT3 pN0 M0
Visc. peritoneum 40 29 no 0 no pT4a pN2b M0 pT4a pN2b M0
Subserosa 15 0 no 0 no pT3 pN0 M0 pT3 pN0 M0
Visc. peritoneum 24 15 no 1 no pT4a pN2b M1a pT4a pN2b M1a
rLN: Number of regional lymph nodes inspected; tp rLN: Number of tumour-positive regional lymph nodes, TD/ Sat.: Tumour deposits/ satellites; MT: Number of distant
metastases; ip MT: Intra-peritoneal metastases
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Fig. 1 N1b representational unit of TNM-O for colorectal tumours. Graph of the patho-anatomical structures represented by an N1b representational
unit of the TNM-O for colorectal tumours version 7 (TNM-O_colorectal_7.owl). T and M representational units are unspecified
Fig. 2 RDF-OWL instance of a tumour aggregate and corresponding OWL classes. Graph of an RDF instance of a tumour aggregate as created from
tabular data according to TNM-O for colorectal tumours version 7 (TNM-O_colorectal_7.owl). RDF instances data are depicted with a purple
diamond. RDF instance for T and M classification are omitted. Instances of this type are classified as TNM N1b
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TNM-O, TNM-O_colorectal_7 and RDF-OWL instance
data.
Discussion
TNM is a globally accepted system to describe the
anatomical extent of malignant tumours [2, 14]. Although
TNM is of high importance for tumour staging, to the
knowledge of the authors, there exists no comprehensive
formal representation of TNM so far. With this work,
the authors provide a first version of a TNM ontology
(TNM-O) and a prototypical implementation of TNM for
colorectal cancers. Further, this work shows that TNM-O
classifies instance data.
Over time, TNM has developed into a coding system,
which had to accommodate both the pragmatics of coding
and representational accuracy. The literature on ambi-
guities and difficulties of TNM in practice is abundant.
The discussion of TNM for breast tumours illustrates
the dilemma of its maintainers [8, 47, 48]. They had to
account for the rapid progression of scientific knowledge
on tumours and to keep it usable at the same time: new
versions of TNM are already outdated when compared
with new scientific insights. On the other hand, TNM has
become increasingly complex, with a negative impact on
its usability by both expert and non-expert documentation
staff and physicians.
Encoding clinical conditions using TNM as well as the
selection of the right treatment according to TNM codes
is daily routine in oncology. In order to assist in these
difficult and time consuming decision processes, sev-
eral systems have been proposed, usually based on text
extraction from pathology reports and machine learn-
ing algorithms [24–26]. The accuracy of these approaches
was relatively low [24]. Here, we present an ontology,
which classifies instance data with 100% accuracy in
an experimental setting based on structured data. We
hypothesise that DL based classification using TNM-O
could also improve the results from automated informa-
tion extraction from unstructured data as done in the
above mentioned approaches. Such systems could also be
made available in intelligent documentation systems in
the form of embedded decision support systems, which
could help to choose the right codes for a clinical condi-
tion and/ or the right guideline compliant treatment for
a given code (describing a clinical condition). Further-
more, we think that with an ontology the curation of the
TNM itself could be improved. Based on a taxonomic
and axiomatic description, the detection of coding errors,
inconsistencies, and ambiguities in definitions could be
facilitated [28, 29]. A formal description logic based
axiomatisation allows the use of specific reasoning tools
to check for inconsistencies during the ontology engi-
neering process, which would indicate conflicting axioms.
Redundancies or wrong hierarchical dependencies is
detected by checking the inferred class hierarchy after DL
classification.
This study is limited as far as we provide here a
first version of the TNM Ontology (TNM-O), limited
to mammary gland [32] and colorectal tumours. As
these two tumour entities are the most complex and
best represented ones in TNM, the current version
is already sufficiently complete and stable to be used
as a blueprint for TNM-O extensions to other organ
systems.
Due to the nature of the domain and the rich top-level
ontology employed, the computational resources needed
to classify the ontology are considerable. In order to
alleviate performance issues, TNM-O will be provided as
modules for different organ systems. Thus, the users can
import only the modules of interest into their application
context.
Future research should evaluate the presented prototype
ontology (i) by implementing further tumour locations,
and (ii) by systematic application in clinical classification
and retrieval scenarios. We will provide the formalization
of TNM for other primary tumour locations in a modu-
lar way, so that users can select which part of the TNM-O
they would like to use. In this way, we hope to reduce the
computational resources already needed to a minimum.
Conclusion
We presented a first version of an ontology (TNM-O) that
represents the TNM tumour classification system. The
present work demonstrates its representational power and
completeness as well as its applicability for classification
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